Coronary Artery Disease, Gout
Conditions
Keywords
Uric, Acid, Level
Brief summary
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
Interventions
DRUGAZD6140
Oral tablets taken bid for 5 days
DRUGPlacebo to match AZD6140
Oral tablets taken bid for 5 days
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Normal physical examination, vital signs, electrocardiogram (ECG) and laboratory values (unless the investigator considers an abnormality not to be clinically significant) * Normal laboratory tests at screening * Non-smoker (no cigarette/tobacco use for at least 6 months)
Exclusion criteria
* Personal or family history of gout, gouty arthritis, or renal stones
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine. | Levels or certain chemicals in subjects' blood and urine will be measured at scheduled times during the first 7 days of the study. |
Secondary
| Measure | Time frame |
|---|---|
| The blood levels of AZD6140 in various subjects on the same diet. | following dosing during the first 5 days of the study |
| The effect of taking AZD6140 on the levels of certain hormones in urine | during the first 5 days of the study |
Outcome results
None listed